No data to show
XNAS
TSVT
Market cap266mUSD
May 12, Last price
5.00USD
Name
2Seventy Bio Inc
Chart & Performance
P/E
—
P/S
7.03
EPS
—
Div Yield, %
—
Shrs. gr., 5y
17.53%
Rev. gr., 5y
-3.09%
Revenues
38m
-62.28%
Net income
-57m
L-73.69%
CFO
-85m
L-49.06%
Earnings
Aug 05, 2025
Profile
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 37,862 -62.28% | 100,387 9.72% | 91,496 67.81% | ||||
Cost of revenue | 76,917 | 247,676 | 274,954 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (39,055) | (147,289) | (183,458) | ||||
NOPBT Margin | |||||||
Operating Taxes | (9) | ||||||
Tax Rate | |||||||
NOPAT | (39,055) | (147,289) | (183,449) | ||||
Net income | (57,247) -73.69% | (217,570) -14.39% | (254,144) -7.99% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 126,863 | 165,533 | |||||
BB yield | -60.29% | -49.57% | |||||
| Debt | |||||||
Debt current | 16,365 | 25,320 | 11,164 | ||||
Long-term debt | 471,069 | 744,699 | 529,180 | ||||
Deferred revenue | 3,918 | 5,000 | |||||
Other long-term liabilities | 1,260 | (241,597) | 2,397 | ||||
Net debt | 273,328 | 548,214 | 272,660 | ||||
| Cash flow | |||||||
Cash from operating activities | (84,998) | (166,858) | (237,134) | ||||
CAPEX | (707) | (13,865) | (22,842) | ||||
Cash from investing activities | 80,763 | 43,861 | 11,697 | ||||
Cash from financing activities | 417 | 127,390 | 166,229 | ||||
FCF | 903 | (128,777) | (169,622) | ||||
| Balance | |||||||
Cash | 174,754 | 216,989 | 266,270 | ||||
Long term investments | 39,352 | 4,816 | 1,414 | ||||
Excess cash | 212,213 | 216,786 | 263,109 | ||||
Stockholders' equity | (568,370) | (511,416) | (296,520) | ||||
Invested Capital | 1,024,153 | 1,286,396 | 884,555 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 52,218 | 49,276 | 35,637 | ||||
Price | 2.94 -31.15% | 4.27 -54.43% | 9.37 -63.44% | ||||
Market cap | 153,521 -27.04% | 210,409 -36.99% | 333,919 -44.76% | ||||
EV | 426,849 | 758,623 | 606,579 | ||||
EBITDA | (31,959) | (137,004) | (171,925) | ||||
EV/EBITDA | |||||||
Interest | 8,514 | ||||||
Interest/NOPBT | |||||||